Blog
RSS FeedPosted by Michael Wonder on 20 Sep 2021
Vertex announces letter of intent with pan-Canadian Pharmaceutical Alliance for public reimbursement of CFTR modulators Extended to Include Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor)
17 September 2021 - Vertex Pharmaceuticals today announced that it has signed a letter of intent with the pan-Canadian Pharmaceutical ...
Posted by Michael Wonder on 14 Sep 2021
Axsome Therapeutics announces FDA acceptance of new drug application for AXS-07 for the acute treatment of migraine
14 September 2021 - Axsome Therapeutics today announced that the U.S. FDA has accepted for filing the Company’s new drug application ...
Posted by Michael Wonder on 24 Aug 2021
Limited access to 'lifesaving' cystic fibrosis drug Trikafta under Pharmaceutical Benefits Scheme
24 August 2021 - A mother whose son lives with cystic fibrosis says young people are dying as they wait for ...
Posted by Michael Wonder on 21 Aug 2021
Cystic fibrosis patients, advocates urge Ontario government to provide ‘miracle drug’ funding
20 August 2021 - An Ontario teen living with Cystic Fibrosis and her mother are hoping to shine a light ...
Posted by Michael Wonder on 14 Aug 2021
Halifax man devastated after insurer reverses decision to cover $25,000 cystic fibrosis drug
13 August 2021 - Stefan Strecko says he's pleaded with Canada Life to cover cost of 'miracle' drug. ...
Posted by Michael Wonder on 12 Aug 2021
FDA grants first of its kind indication for chronic sleep disorder treatment
12 August 2021 - The U.S. Food and Drug Administration today approved a new indication for Xywav for idiopathic hypersomnia in ...
Posted by Michael Wonder on 12 Aug 2021
Jazz Pharmaceuticals announces U.S. FDA approval of Xywav (calcium, magnesium, potassium and sodium oxybates) oral solution for idiopathic hypersomnia in adults
12 August 2021 - Xywav is the first and only FDA approved treatment for idiopathic hypersomnia. ...
Posted by Michael Wonder on 31 Jul 2021
Frustrated cystic fibrosis patient speaks out after drug coverage denial
30 July 2021 - Twenty eight year old cystic fibrosis patient Stefan Strecko says he went from jubilation to devastation ...
Posted by Michael Wonder on 27 Jul 2021
Sol-Gel Technologies announces FDA approval of Twyneo
27 July 2021 - Twyneo utilizes Sol-Gel’s proprietary microencapsulation technology and is patent protected until 2038. ...
Posted by Michael Wonder on 21 Jul 2021
New treatment authorised and available for Canadians with HER2 positive breast cancer
20 July 2021 - Phesgo, a fixed dose combination of pertuzumab and trastuzumab for subcutaneous injection combines two treatments into ...
Posted by Michael Wonder on 20 Jul 2021
Japan becomes first country to approve Regeneron antibody cocktail (casirivimab and imdevimab) for the treatment of mild to moderate COVID-19
20 July 2021 - Regeneron Pharmaceuticals today announced that Japan's Ministry of Health, Labour and Welfare has approved Regeneron's casirivimab and ...
Posted by Michael Wonder on 15 Jul 2021
G-BA sees “considerable additional benefit” in two active ingredients - EU HTA analysis is coming
15 July 2021 - The Federal Joint Committee (G-BA) today certified two active ingredients with a "considerable additional benefit". It assigns ...
Posted by Michael Wonder on 15 Jul 2021
Cystic fibrosis patients upset over recommended restrictive criteria for life saving drug
15 July 2021 - 'By narrowly defining accessibility and continuation criteria CADTH’s recommendation overlooks many of Trikafta’s significant benefits,' says chief ...
Posted by Michael Wonder on 13 Jul 2021
'A price on your life': Toronto cystic fibrosis patients slam review process while waiting for access to life-saving treatment
13 July 2021 - While Health Canada approved Trikafta for patient use on June 18, 2021, it is still not ...
Posted by Michael Wonder on 08 Jul 2021
Health Canada approves Vyxeos, the first chemotherapy advance in over 40 years for adults with high-risk acute myeloid leukaemia
7 July 2021 - Jazz Pharmaceuticals today announced the Health Canada approval and availability of Vyxeos (daunorubicin and cytarabine liposome for ...